Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA

Christopher J. Rapuano, MD, discusses emergency eye care access, retina advances and responsible AI use in ophthalmology.

Carreño discusses oral protein-folding correction for RHO-adRP, early-phase trial end points and genetic eligibility.

Phase 3 SLO-RP Preserve will test whether oral NPI-001 slows photoreceptor loss in retinitis pigmentosa due to Usher syndrome.

FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.

In the latest episode of The Wills Retina Report, Regillo and Ho discuss where gene therapy stands for retinal disease, from late-stage programs in neovascular age-related macular degeneration to earlier efforts in geographic atrophy and diabetic retinopathy.

IRIS Registry data showed no change in anti-VEGF frequency, vision, or retinal thickness after patients with DME began a GLP-1RA.

CHMP backs Accord Healthcare’s Lucentis biosimilar Fovlussea for nAMD, DMO, RVO and CNV ahead of an EC decision.

Duravyu missed wet AMD noninferiority twice, DAYBREAK met its end points, and optogenetics won the Nobel as son-vec posted 4-year RP data in an AAO-driven October.